📊 GTBP Key Takeaways
Is GT Biopharma, Inc. (GTBP) a Good Investment?
GT Biopharma is a pre-revenue pharmaceutical company experiencing severe financial distress with $12.9M annual cash burn against only $6.8M in cash reserves, creating a 6-month operational runway. Despite marginal improvement in losses year-over-year, zero revenue generation, total absence of capital investment, and negative ROE/ROA of -490%/-349.8% indicate fundamental business viability failure.
GT Biopharma is a pre-revenue biotech with sustained operating losses and extremely negative returns on equity and assets. Cash (~$6.8M) is well below annual operating cash burn (~$12.9M), implying a near-term financing need and dilution risk. While the balance sheet is debt-free with a solid current ratio, fundamentals show no visibility to revenue or profitability.
Why Buy GT Biopharma, Inc. Stock? GTBP Key Strengths
- Strong liquidity position with 3.50x current ratio and $6.8M cash on hand
- Zero debt burden provides financial flexibility and avoids bankruptcy risk from leverage
- Improving net loss trend with 17.7% YoY improvement reducing operating burn
- Debt-free capital structure with low liabilities
- Solid liquidity (current/quick ratio 3.5x)
- Net loss improved YoY
GTBP Stock Risks: GT Biopharma, Inc. Investment Risks
- Zero revenue generation indicating complete failure to commercialize products or execute business model
- Cash runway of only ~6 months at current burn rate of $12.9M annually
- Severely negative returns on equity (-490%) and assets (-349.8%) destroying shareholder value
- No capital expenditure or R&D investment visible suggesting stalled product development
- Deeply negative EPS of -$6.68 per share unsustainable long-term
- Zero insider buying activity in 90 days indicates no management confidence in recovery
- Zero revenue and no gross profit
- High cash burn relative to cash balance (short runway)
- Likely dilution/going-concern risk to fund operations
Key Metrics to Watch
- Monthly cash burn rate and remaining liquidity runway
- Revenue initiation or clinical trial milestone announcements
- Operating cash flow stabilization or improvement
- Debt issuance or equity raise announcements indicating survival financing needs
- Operating cash flow (cash burn)
- Cash & equivalents (runway in months)
GT Biopharma, Inc. (GTBP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.50x current ratio provides a solid financial cushion.
GTBP Profit Margin, ROE & Profitability Analysis
GTBP vs Healthcare Sector: How GT Biopharma, Inc. Compares
How GT Biopharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GT Biopharma, Inc. Stock Overvalued? GTBP Valuation Analysis 2026
Based on fundamental analysis, GT Biopharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GT Biopharma, Inc. Balance Sheet: GTBP Debt, Cash & Liquidity
GTBP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: GT Biopharma, Inc.'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-6.94 indicates the company is currently unprofitable.
GTBP Revenue Growth, EPS Growth & YoY Performance
GTBP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | N/A | $1.9M | N/A |
| Q2 2021 | N/A | $1.6M | N/A |
| Q1 2021 | N/A | -$1.7M | N/A |
| Q1 2020 | N/A | -$1.7M | $-0.02 |
| Q1 2019 | N/A | -$4.5M | $-0.09 |
| Q2 2018 | N/A | -$2.5M | $335,450.00 |
| Q1 2018 | N/A | -$5.1M | $-0.20 |
| Q3 2017 | N/A | -$3.6M | $-8.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GT Biopharma, Inc. Dividends, Buybacks & Capital Allocation
GTBP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for GT Biopharma, Inc. (CIK: 0000109657)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GTBP
What is the AI rating for GTBP?
GT Biopharma, Inc. (GTBP) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 83% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GTBP's key strengths?
Claude: Strong liquidity position with 3.50x current ratio and $6.8M cash on hand. Zero debt burden provides financial flexibility and avoids bankruptcy risk from leverage. ChatGPT: Debt-free capital structure with low liabilities. Solid liquidity (current/quick ratio 3.5x).
What are the risks of investing in GTBP?
Claude: Zero revenue generation indicating complete failure to commercialize products or execute business model. Cash runway of only ~6 months at current burn rate of $12.9M annually. ChatGPT: Zero revenue and no gross profit. High cash burn relative to cash balance (short runway).
What is GTBP's revenue and growth?
GT Biopharma, Inc. reported revenue of $0.0.
Does GTBP pay dividends?
GT Biopharma, Inc. pays dividends, with $0.2M distributed to shareholders in the trailing twelve months.
Where can I find GTBP SEC filings?
Official SEC filings for GT Biopharma, Inc. (CIK: 0000109657) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GTBP's EPS?
GT Biopharma, Inc. has a diluted EPS of $-6.68.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GTBP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, GT Biopharma, Inc. has a STRONG SELL rating with 83% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GTBP stock overvalued or undervalued?
Valuation metrics for GTBP: ROE of -490.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GTBP stock in 2026?
Our dual AI analysis gives GT Biopharma, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GTBP's free cash flow?
GT Biopharma, Inc.'s operating cash flow is $-12.9M, with capital expenditures of $0.0.
How does GTBP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -490.0% (avg: 15%), current ratio 3.50 (avg: 2).